Pharmacy Financing: Buy It or Fund the Float
Buying an independent pharmacy runs on an SBA 7(a): one loan at about 10% down that funds the business and the drug inventory together. What sinks first-time buyers is the cash timing. You pay the wholesaler in 15 to 30 days while the payers reimburse weeks later, so the real capital need is the float between dispensing a prescription and getting paid for it, not the sticker price on the shelf.
Bottom line
An SBA 7(a) is how most independent pharmacy purchases get funded: one loan, up to $5 million, about 10% down, ten years to repay, covering the business and the drug inventory together. The inventory is the undercounted part. A $600,000 store usually carries $250,000 to $400,000 of drugs at cost, so the real project is closer to $900,000. The part that decides whether you survive the first year is the reimbursement float: a pharmacy pays its wholesaler in 15 to 30 days while payers pay weeks later, so a line of credit sized to that gap matters as much as the purchase loan. Underwrite the payer and gross-margin mix, not the script count.
There is no single “pharmacy loan”
The right product follows the job. Are you buying the store, carrying the inventory and reimbursement gap, or adding a dispensing robot? A purchase is an acquisition, and because most of the price is goodwill and drugs a bank cannot easily resell, acquisitions go through the SBA 7(a). The ongoing float is a line of credit. New automation is an equipment purchase. Different loans, each with its own down payment, timeline, and credit bar.
The purchase is where the money and the mistakes are, so start there. At bottom an independent pharmacy is a small business sold on its cash flow and the strength of its payer contracts, the same mechanics the guide to financing a business purchase lays out, and the acquisition loan versus SBA 7(a) comparison sets side by side. What makes a pharmacy its own animal is the drug inventory, the reimbursement lag that funds itself out of your cash, and the regulatory transfers that gate the close.
One rule before anything else: never buy a store on a merchant cash advance or a short-term loan. Pharmacies get pitched daily-debit advances constantly because the deposits look strong, and a merchant cash advance is a bridge at best and a trap at worst. Acquisition debt belongs on the SBA. The nearest relatives to this deal are the medical practice and the liquor store: a healthcare operation with insurance-paid revenue on one side, a heavy inventory bought at cost on the other.
Which product fits which job
Six jobs, six products. Pick the money that fits the task instead of the lender who calls first, and the rate and the paperwork sort themselves out.
Reference current as of October 2026, with Prime near 7.5%. Figures are typical marketplace ranges, vary by lender and by state, and are no guarantee of approval. Verify current terms before relying on any number.
Buying an existing independent pharmacy (business only)
Product
SBA 7(a) acquisition loan
Typical terms
10% down, 10-year term
The standard path when you lease the space and buy the operation. A 7(a) rolls the goodwill, the drug inventory you inherit, and a working-capital cushion into one loan up to $5 million, which is why a conventional bank passes on a goodwill-heavy store and the SBA does not. You put in a 10% equity injection, a standby seller note can carry part of it, and the loan is sized off provable script volume and payer remittances, not the broker's revenue claim.
Buying the pharmacy and the building
Product
SBA 7(a) up to $5M, or a 7(a) + 504 pairing
Typical terms
10% to 15% down, up to 25-year real estate term
Owning the building removes the lease risk that can end a pharmacy at renewal, which matters when the business is bolted to a specific corner and a prescriber base nearby. A single 7(a) can fund the whole thing up to $5 million, or the real estate goes on a 504 at a long fixed rate while the 7(a) handles the business and the inventory. Lenders treat owned real estate as a credit strength because it adds a hard asset to a balance sheet that is otherwise mostly goodwill and drugs.
Opening a new pharmacy from scratch
Product
SBA 7(a) with buildout plus working capital
Typical terms
10% to 20% down, buildout plus a funded ramp
Ground-up is the hard version, because a new store has no script file and no payer contracts the day it opens. You carry a 60-to-120-day stretch enrolling in PBM networks and getting the NCPDP and NPI numbers that let payers pay you at all, and you stock a full shelf of inventory before the first reimbursement lands. Fund the ramp and the opening inventory inside the loan, not out of a register that is not ringing yet.
The inventory and reimbursement float
Product
Business line of credit
Typical terms
$10K to $250K, revolving
This is the quiet one, and the product most owners actually live on. You pay the wholesaler in 15 to 30 days and the payers reimburse weeks later, so a line of credit carries the gap and costs nothing on the undrawn balance. Size it to the float, draw it as inventory ships, and pay it down as remittances land. A revolving line is the right tool here, far cheaper than a daily-debit advance against the same gap.
A dispensing robot, POS, or compounding equipment
Product
Equipment financing
Typical terms
$10K to $500K, 2 to 7 years
A dispensing robot, a compounding hood, or a full point-of-sale and pharmacy-management system are long-life assets that belong on a matched term, not on this month's cash. The equipment secures the loan, so the bar to qualify sits lower than on unsecured credit, and the automation usually pays part of its own payment by freeing a technician's hours for the clinical and front-end work that actually earns margin.
A short gap or a slow stretch
Product
Revenue-based advance (bridge only)
Typical terms
$10K to $250K, fast
Pharmacies get pitched daily-debit cash advances hard, because the deposit history looks strong on a bank statement. Price one honestly as a factor rate with daily or weekly debits, and use it only as a bridge to a payoff you can name and date, never as base capital and never stacked. A quarter-million in acquisition debt cannot ride on a product built for a four-month gap, and stacking advances is the fastest way a busy store goes broke.
One application shows which of these your file qualifies for, with a soft pull that costs no points. See your real options. If the job is the ongoing inventory and reimbursement gap rather than a purchase, the business line of credit page covers current amounts, and new automation goes on equipment financing.
What a $600,000 pharmacy actually costs to buy
The listing price is only part of the capital you need, and the drug inventory is the part first-time buyers forget to fund. Walk a generic store through the numbers. The arithmetic below is illustrative, so re-run it with your own figures, a real inventory valuation, and a current quote.
The asking price
$600,000
An established store priced on its script file, its payer mix, and the goodwill of a loyal patient base, typically some multiple of annual cash flow for the business alone. That multiple is where the negotiation lives, and the payer mix behind the revenue, not the raw script count, is the lever most first-time buyers never pull.
The inventory you buy at cost
+ $250,000 to $400,000
A pharmacy carries a deep shelf of brand and generic drugs, and that inventory transfers at cost on top of the business price. It is a real, bankable asset, so it belongs inside the acquisition loan rather than scraped together in cash at closing. A deal that ignores it is not a cheaper deal, it is an undercounted one.
The smart capital need
about $900,000
Fold $300,000 of inventory into the $600,000 business and the project is about $900,000 of total cost before a working-capital line. An SBA 7(a) can finance the business, the inventory, and a cushion in one loan, which beats buying the store now and discovering the float eats your cash two months in.
Your cash in
about $90,000
A 10% equity injection on the $900,000 project. A standby seller note, where the seller sits behind the SBA for the life of the loan, can count toward that injection and push the cash out of your own pocket toward 5%, which on a pharmacy keeps powder dry for the reimbursement float.
The monthly payment, and the test it has to pass
Finance the full $900,000 project on an SBA 7(a) with a $90,000 injection, and the roughly $810,000 loan at an illustrative 10.25% over ten years runs about $10,820 a month, near $130,000 a year. A lender wants that covered at least 1.15 times, so the store has to show about $149,000 a year in provable free cash flow after a market pharmacist-manager’s wage. Buy the business alone and ignore the inventory, and the payment looks smaller, but you will fund that $300,000 of drugs and the reimbursement float out of cash, with no cushion left for the first slow month. Folding the inventory into the loan and opening a line for the float is what keeps the doors open.
Ten percent is the usual injection on an acquisition, and a standby seller note can shoulder part of it, as the SBA down payment guide spells out. For how a lender turns documented cash flow into a maximum loan amount, the SBA qualification walkthrough covers the coverage math that sets the ceiling.
The business runs on the gap between buying a drug and getting paid
And a lien you never see coming can stall the close.
Few pharmacy guides touch this, and it is the whole ballgame on whether a store survives its first year under new ownership. A pharmacy is not really a retail shop, it is a third-party billing operation with a drawer of expensive inventory. What a lender and a sharp buyer actually weigh, roughly in the order it moves the deal:
You pay the wholesaler before the payer pays you
This is the whole shape of the business, and the thing most pharmacy guides skip. More than nine in ten scripts are billed to a third party, and the pharmacy benefit manager or insurer reimburses weeks after you dispense, while the wholesaler that supplied the drug wants paying in 15 to 30 days. So the store funds a widening pile of unpaid claims out of its own cash, and the busier it gets, the bigger that pile grows. The capital need is not the shelf, it is the gap between buying the drug and getting paid for it. Size a line of credit to that float before anything else.
Since 2024, price concessions hit at the point of sale
A 2022 CMS rule took effect January 1, 2024, requiring Medicare Part D pharmacy price concessions, the old retroactive DIR fees, to be reflected at the point of sale instead of clawed back months later. That ended the surprise clawbacks that used to wreck a quarter, but it also lowered the up-front reimbursement on each affected claim, and some generics now reimburse below acquisition cost. Underwrite the gross-margin mix, not the script count: two stores filling the same number of prescriptions can earn very different money depending on payer and drug mix.
The wholesaler's lien can sit ahead of your lender
Independents usually sign a primary-vendor agreement committing most of their buying to one wholesaler for better pricing, and that wholesaler commonly holds a security interest in the inventory and receivables it finances. Your acquisition lender wants a blanket UCC-1 lien on the same assets. Those two claims collide, and sorting the priority through a subordination or intercreditor agreement is a real step that can stall an otherwise approved close. Raise it early, because discovering it at the closing table costs weeks.
So anchor the deal to the documented payer mix and the inventory valuation, then plan the working-capital line and the lien subordination before you sit at a closing table. The seller’s revenue headline is a bargaining line, not something a lender will fund, and whatever sits between the headline and the remittance records is cash out of your own pocket. The federal rule behind the point-of-sale change is laid out by CMS, and the SBA’s own 7(a) program page covers acquisition eligibility.
What controls the close besides the loan
Money in hand is not the same as doors open. Three things the lender does not control decide whether, and how quickly, you close: the payer contracts, the licensing, and whether the volume records hold up. Start all three early, before you pay for serious diligence.
The payer contracts and provider numbers have to carry over
A pharmacy earns almost nothing without its PBM network contracts and its NCPDP and NPI provider numbers, and a change of ownership can force re-enrollment rather than a clean transfer. Re-credentialing with the networks takes time, and every week a contract is not live is a week of scripts you cannot bill. Map which agreements assign and which must be rebuilt before you set a closing date, and fund a cushion for any gap.
The license, the DEA registration, and the board sign-off set the date
A pharmacy runs on a state board license, a DEA registration for controlled substances, and in most states a licensed pharmacist in charge, and the change-of-ownership approvals on those, not the loan, usually set your closing date. Most states require a licensed pharmacist in the ownership or in the pharmacist-in-charge role, so confirm your state's rule early. Start the transfers the day you have a signed letter of intent, because the regulators move on their own clock.
Verify the volume and the payer mix before you price the offer
Ask for the dispensing-system reports, the payer remittance records, and twelve months of wholesaler purchase statements, then cross-check them against the tax returns. Two pharmacies with identical script counts can be worth very different money once you see the payer and generic mix underneath. The documented, bankable number is what those records support, not the seller's revenue headline, and the gap between the two is cash out of your pocket.
Own the building and one more risk disappears, the chance a landlord ends your run at renewal on a store bolted to its prescriber base. For the ordinary month-to-month swings a pharmacy lives with between remittances, a business line of credit carries the gap and costs nothing on the undrawn balance.
How to line the deal up before you apply
What separates a smooth close from a stalled one is rarely the lender, it is what you brought to the table. Four moves clear the snags that actually hang up a pharmacy deal.
Decide what you are actually financing
Buying the operation points to an SBA 7(a). Add the building and you add a 504 or a larger 7(a). The ongoing inventory and reimbursement float is a line of credit. A dispensing robot is equipment financing. Pin the job down first, because the job chooses the product, and the product fixes your down payment, your timeline, and your paperwork.
Pull the dispensing reports, remittances, and wholesaler statements early
An acquisition 7(a) runs on the seller's two most recent tax returns, a year-to-date profit and loss, the lease with assignment language, and a full inventory valuation. The pieces specific to this business are the dispensing-software reports, the payer remittance detail, and the wholesaler purchase history, and having them in hand up front is the single biggest thing that moves a close from ninety days toward forty-five.
Roll the inventory into the acquisition loan and size a line for the float
The common first-timer mistake is financing only the business price, paying cash for the inventory, then running dry when the reimbursement gap shows up a month later. Finance the inventory inside the purchase, where the rate is lower and the term is longer, and open a working-capital line at the same time, sized to the float, so the first slow stretch is a draw and not a crisis.
Start the license, DEA, and PBM transfers the day you sign the letter of intent
The paperwork that actually hangs up a pharmacy deal is regulatory, not financial. Line up the state board change of ownership, the DEA registration, and the PBM network re-enrollment on day one, and confirm the primary-vendor agreement and any wholesaler lien so the subordination is handled before closing rather than discovered during it.
Already own a store and just need capital? The same discipline scales down: borrow to the job and hold a cushion. A dispensing robot at about $120,000, financed over seven years near 9.5%, runs roughly $1,960 a month, and the technician hours it frees fund part of that payment. Before you sign anything, it helps to know what lenders actually require to qualify.
See what your pharmacy deal qualifies for
A single 2-minute application goes to 300+ lenders at once: SBA Preferred Lenders who fund pharmacy buyouts, line-of-credit providers who carry the reimbursement float, and equipment specialists for dispensing automation. The pull is soft, so a look costs you nothing on your score, and no offer carries any obligation.
Frequently asked questions
Can you get an SBA loan to buy a pharmacy?
Yes, and the SBA 7(a) is the most common way independent pharmacy acquisitions get financed. A 7(a) can fund the business, the drug inventory, and a working-capital cushion in one loan up to $5 million, typically at a 10% equity injection over a 10-year term. A retail pharmacy is an eligible business, and lenders size the loan off provable script volume and payer remittances rather than the asking price. The inventory you buy at cost can usually be rolled into the same purchase loan.
How much does it cost to buy an independent pharmacy?
The business alone often trades on a multiple of its annual cash flow, and many independent stores land somewhere in the mid six figures, with larger or real-estate-included deals running past a million. The figure buyers miss is inventory. A pharmacy carries $250,000 to $400,000 or more of drugs on the shelf at cost, and that transfers on top of the business price, so budget the deal as the business plus the inventory plus a working-capital line for the reimbursement float.
How do lenders verify a pharmacy's income?
Through the dispensing system and the payer remittances, cross-checked against the tax returns. Because almost all revenue is billed to third parties, a lender reads the pharmacy-management reports, the PBM and insurer remittance detail, and twelve months of wholesaler purchase statements to confirm real volume and real margin. Script count alone is not enough, because payer and drug mix drive what the store actually earns. The fundable number is what those records support, not the seller's revenue story.
What are DIR fees, and did they go away in 2024?
DIR fees were retroactive price concessions that pharmacy benefit managers clawed back months after a Medicare Part D script was filled, often turning a profitable quarter into a loss. A CMS rule effective January 1, 2024 moved those concessions to the point of sale, which ended the retroactive clawbacks but lowered the up-front reimbursement on affected claims. The net effect for a buyer is more predictable cash flow and a sharper need to underwrite each store's real gross-margin mix.
What credit score and experience do I need?
Plan on a personal score near 680 and a clean record for an SBA pharmacy acquisition loan. Most states require a licensed pharmacist in the ownership or as the pharmacist in charge, and lenders generally want evidence of pharmacy operating experience plus a staffing plan. If you already own a store, equipment and revenue-based products bend further on credit, because they underwrite the machines or your deposits rather than your credit file alone.
Can I finance inventory or a dispensing robot for a pharmacy I already own?
Yes. A business line of credit is the right tool for inventory and the reimbursement float, because you draw only what you need and pay interest only on the drawn balance. A dispensing robot, compounding equipment, or a pharmacy-management system goes on equipment financing from $10,000 to $500,000 over 2 to 7 years, secured by the equipment itself, usually with approvals in days rather than weeks.
Quick Loans Direct is a lending marketplace, not a direct lender. Actual rates, terms, and approval decisions are made by our lending partners based on their individual underwriting criteria and vary by borrower, product, and the pharmacy’s financials. The figures shown here are typical marketplace ranges, not guarantees of approval. Rates and terms may vary by state. California, New York, Virginia, Utah, Georgia, Connecticut, Florida, Kansas, and several other states require specific commercial-financing disclosures that your chosen lender will provide.
This content is for informational purposes only and does not constitute financial, tax, or legal advice. Consult a qualified professional before making business financing decisions. Last reviewed by the Quick Loans Direct editorial team on October 2026.